CGTX · XBRL financial data

Cognition Therapeutics financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CGTX's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	18,572	30,324	37,196	41,676	37,187
General and administrative	10,026	13,227	13,528	12,290	10,612
Total operating expenses	28,598	43,551	50,724	53,966	47,799
Operating income (loss)	(28,598)	(43,551)	(50,724)	(53,966)	(47,799)
Interest expense	895	—	—	—	—
Other income (expense)	16,882	22,154	24,936	19,995	24,312
Income tax expense (benefit)	0	0	0	0	0
Net income (loss)	(11,716)	(21,397)	(25,788)	(33,971)	(23,487)
Earnings per share, basic USD per share	(3.13)	(0.91)	(0.86)	(0.86)	(0.32)
Earnings per share, diluted USD per share	(3.13)	(0.91)	(0.86)	(0.86)	(0.32)
Weighted average shares, basic thousands of shares	5,191	23,640	30,029	39,730	72,767
Weighted average shares, diluted thousands of shares	5,191	23,640	30,029	39,730	72,767

Fiscal years (CGTX's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	54,721	41,562	29,922	25,009	36,810
Total current assets	58,992	47,647	34,222	29,555	47,991
Property and equipment, net	145	233	284	181	93
Right-of-use asset	—	813	657	498	306
Total assets	59,137	50,425	35,163	30,234	48,390
Accounts payable	4,168	3,216	3,695	1,984	1,119
Accrued liabilities	1,751	2,094	4,055	7,620	11,995
Total current liabilities	7,864	7,795	10,169	11,142	13,924
Lease liability, non-current	—	695	520	342	195
Total liabilities	7,864	10,176	10,689	11,484	14,119
Accumulated deficit	(94,004)	(115,401)	(141,189)	(175,160)	(198,647)
Total stockholders' equity	51,273	40,249	24,474	18,750	34,271
Total liabilities and equity	59,137	50,425	35,163	30,234	48,390
Common shares outstanding (cover page) thousands of shares	22,579	29,263	39,000	61,973	89,354

Fiscal years (CGTX's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(11,716)	(21,397)	(25,788)	(33,971)	(23,487)
Stock-based compensation	5,183	3,572	4,354	3,748	2,087
Depreciation and amortization	93	83	96	107	36
Net cash from operating activities	(3,631)	(18,533)	(16,018)	(28,474)	(24,588)
Purchases of property and equipment	27	171	147	4	—
Net cash from investing activities	(27)	(171)	(147)	(4)	9
Net cash from financing activities	53,201	5,546	4,521	23,565	36,570
Net change in cash	49,532	(13,159)	(11,640)	(4,913)	11,991

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Cognition Therapeutics	34,012	not reported	(3,053)*	95.1M	11.1 quarters	Q2 FY26 10-QJun 30, 2026
Charlie's Holdings	527	not reported	(383)*	280.6M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
IGC Pharma	331	265	(1,350)*	103.4M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Ernexa Therapeutics	5,028	not reported	(4,152)*	1.6M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Relmada Therapeutics	11,334	not reported	(9,606)*	106.7M	22.7 quarters	Q2 FY26 10-QJun 30, 2026
CEL-SCI	6,527	not reported	(4,031)*	17.6M	1.6 quarters	Q3 FY26 10-QJun 30, 2026
Marker Therapeutics	11,331	not reported	(3,716)*	16.7M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Lipocine	4,979	190	(3,028)*	8.2M	7.7 quarters	Q2 FY26 10-QJun 30, 2026
Fibrogen	50,644	(1,474)	(3,991)*	4.0M	22.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.